Beijing Huasu Salt Hydrochloride Naltrexone Tablets, a subsidiary of CENTEK, passed the consistency evaluation
I'm PortAI, I can summarize articles.
Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of CENTEK, recently received approval from the National Medical Products Administration for the hydrochloride naltrexone tablets (50mg) to pass the consistency evaluation of generic drug quality and efficacy. This medication is used for detoxification and relapse prevention in opioid-dependent individuals. The hydrochloride naltrexone tablets are the first variety in China to pass the consistency evaluation, with a cumulative research and development cost of 11.7389 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments